“Age Reversal Is Coming.” Inside The First Human Trials - Dr David Sinclair - #1141

What It Covers

Dr. David Sinclair, Harvard longevity researcher, details the first human trials of epigenetic age-reversal gene therapy targeting blindness, explains the information theory of aging, and outlines his current supplement and drug protocol. He covers fasting strategies, exercise recommendations, GLP-1 drugs, NAD supplementation controversies, and the trajectory toward whole-body biological rejuvenation within this decade.

Key Questions Answered

• •Epigenetic Age Reversal (OSK Gene Therapy): Sinclair's lab uses three Yamanaka factors — Oct4, Sox2, and Klf4 (OSK) — delivered via viral particles to reverse cellular aging without erasing cell identity. The critical breakthrough was omitting the c-MYC gene, which stops reprogramming at roughly 75% reversal, preventing cancer or stem-cell conversion. Human trials are now underway targeting glaucoma and macular degeneration, the two leading causes of blindness globally, with results showing efficacy across multiple tissue types in primates.
• •Oral Rejuvenation Pill (Unpublished Lab Data): Sinclair reveals his lab has developed an oral compound — administered three days per week for one month in aged mice — that produces measurable rejuvenation including improved memory and skin quality. The mechanism involves TET enzymes that strip chemical tags off DNA, resetting the epigenome. Critically, blocking TET enzymes eliminates the effect, confirming the pill works through genuine epigenetic reset rather than cellular stress response.
• •Fasting Protocol and Extended Caloric Restriction: Sinclair eats one to two meals daily, skipping breakfast, and periodically fasts for up to two weeks while maintaining vitamin and mineral supplementation. After three days of fasting, chaperone-mediated autophagy (CMA) activates, clearing misfolded proteins linked to accelerated aging. Time-restricted eating within a defined daily window produces substantially greater longevity benefits in animal studies than equivalent caloric restriction spread across continuous feeding, regardless of macronutrient composition.
• •Protein Pulsing and mTOR Management: Constant high animal-protein intake keeps mTOR chronically active, which accelerates aging in animal models despite building muscle. Branched-chain amino acids — leucine, isoleucine, and valine — found in higher concentrations in animal protein than plant protein, correlate with shorter lifespan when consumed in excess. Sinclair recommends cycling: eat higher animal protein around training periods to stimulate mTOR, then shift to predominantly plant protein or fasting phases to allow mTOR suppression and activate longevity pathways.
• •Daily Drug and Supplement Stack: Sinclair's current morning protocol includes approximately one gram of resveratrol mixed with olive oil or yogurt, NMN as an NAD precursor, alpha-lipoic acid, CoQ10, low-dose tadalafil (Cialis) for vascular blood flow and potential cancer-immune modulation, one baby aspirin (81mg) due to elevated lipoprotein(a), and nattokinase (10,000 units) for potential arterial plaque reduction. He monitors outcomes via CGM, smart scale with body composition, HRV tracking, annual carotid ultrasound, and regular blood panels.
• •NMN Supplement Contamination Warning: Independent testing by researcher Andrea Meyer in Singapore found many commercial NMN supplements contain less NMN than labeled. Sinclair's own lab discovered endotoxin contamination — bacterial byproducts causing inflammation — in bulk NMN used in mouse studies, invalidating early longevity experiments. To reduce risk, consumers should select brands that publish third-party batch analytics, carry GMP certification, and USP labeling. Sinclair states he has no financial relationship with any supplement brand despite widespread unauthorized use of his name in marketing.
• •GLP-1 Receptor Agonists as Longevity Drugs: Sinclair considers GLP-1 drugs the closest currently available intervention to a genuine longevity compound, citing emerging evidence of benefits beyond weight loss including brain health protection, immune modulation, and dementia risk reduction through mechanisms independent of caloric restriction alone. He personally trialed low-dose GLP-1 and observed appetite suppression and easier weight management. Known risks include rare kidney complications and vision issues. He recommends physician supervision, particularly for individuals already near metabolic optimum.